Novo Nordisk (NYSE: NVO) is a large drug maker that built its business around treating diabetes.
That was how it got into the GLP-1 weight-loss drug space
However, the opportunity for weight-loss drugs is much larger than the diabetes market. The company is working through a transition year, but if you are a dividend investor, that could be your opportunity to buy this high-yield stock. Here’s what you need to know.
How attractive is Novo Nordisk’s dividend yield? Novo Nordisk’s dividend yield is 3.5%. That is much higher than the roughly 1% yield you’d collect from an S&P 500 index (SNPINDEX: ^GSPC) fund.